Weight Wellness Study

Purpose: to evaluate the safety and tolerability of a potential new drug that would prevent weight regain after stopping obesity treatment with GLP-1’s.

This study has 1 screening appointment, 5 outpatient visits, 5 phone calls and at home dosing.

Participants must be comfortable dosing twice a day at home (30 min before breakfast & 30 min before dinner).

Reimbursement for study participation will be provided for time and travel of up to $7,280.

Study Treatment Period: Participants must be willing to discontinue semaglutide or tirzepatide for the treatment period of this study under Nucleus Network supervision.

This study has been reviewed by an Institutional Review Board.

Call 612-315-6490 to discuss your eligibility today!